JP5891235B2 - Ｃ型肝炎ウイルスの新規阻害剤 - Google Patents

Ｃ型肝炎ウイルスの新規阻害剤 Download PDF

Info

Publication number
JP5891235B2
JP5891235B2 JP2013537808A JP2013537808A JP5891235B2 JP 5891235 B2 JP5891235 B2 JP 5891235B2 JP 2013537808 A JP2013537808 A JP 2013537808A JP 2013537808 A JP2013537808 A JP 2013537808A JP 5891235 B2 JP5891235 B2 JP 5891235B2
Authority
JP
Japan
Prior art keywords
alkyl
mmol
methyl
carbonyl
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013537808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544812A (ja
JP2013544812A5 (enExample
Inventor
ロバート マーレー マッキネル，
ロバート マーレー マッキネル，
ダニエル ディー． ロン，
ダニエル ディー． ロン，
オルデン， ロリ ジーン ヴァン
オルデン， ロリ ジーン ヴァン
ラン ジャン，
ラン ジャン，
マンディー ルー，
マンディー ルー，
ダイスケ ローランド サイトウ，
ダイスケ ローランド サイトウ，
シーラ ジップフェル，
シーラ ジップフェル，
エリック エル． スタンジェランド，
エリック エル． スタンジェランド，
カサンドラ リパック，
カサンドラ リパック，
ギャビン オガワ，
ギャビン オガワ，
シャオジュン ファン，
シャオジュン ファン，
ウェイジャン ザン，
ウェイジャン ザン，
Original Assignee
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー, セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー filed Critical セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Publication of JP2013544812A publication Critical patent/JP2013544812A/ja
Publication of JP2013544812A5 publication Critical patent/JP2013544812A5/ja
Application granted granted Critical
Publication of JP5891235B2 publication Critical patent/JP5891235B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2013537808A 2010-11-04 2011-11-03 Ｃ型肝炎ウイルスの新規阻害剤 Expired - Fee Related JP5891235B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41026710P 2010-11-04 2010-11-04
US61/410,267 2010-11-04
US201161444046P 2011-02-17 2011-02-17
US61/444,046 2011-02-17
US201161492267P 2011-06-01 2011-06-01
US61/492,267 2011-06-01
PCT/US2011/059061 WO2012061552A1 (en) 2010-11-04 2011-11-03 Novel inhibitors of hepatitis c virus

Publications (3)

Publication Number Publication Date
JP2013544812A JP2013544812A (ja) 2013-12-19
JP2013544812A5 JP2013544812A5 (enExample) 2014-11-06
JP5891235B2 true JP5891235B2 (ja) 2016-03-22

Family

ID=44993923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537808A Expired - Fee Related JP5891235B2 (ja) 2010-11-04 2011-11-03 Ｃ型肝炎ウイルスの新規阻害剤

Country Status (9)

Country Link
US (2) US8921372B2 (enExample)
EP (1) EP2635571B1 (enExample)
JP (1) JP5891235B2 (enExample)
CN (1) CN103189371B (enExample)
AR (1) AR083757A1 (enExample)
CA (1) CA2814534A1 (enExample)
ES (1) ES2548286T3 (enExample)
TW (1) TW201249827A (enExample)
WO (1) WO2012061552A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014532716A (ja) * 2011-11-03 2014-12-08 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー フラグメント｛２−［４−（ビフェニル−４−イル）−１ｈ−イミダゾ−２−イル］ピロリジン−１−カルボニルメチル｝アミンを含む棒状ｃ型肝炎ウイルス阻害剤

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921732B2 (en) * 2007-06-12 2014-12-30 Revolaze, LLC High speed and high power laser scribing methods and systems
PL2368890T3 (pl) 2009-06-11 2013-10-31 Abbvie Bahamas Ltd Inhibitory wirusa zapalenia wątroby C
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012061552A1 (en) * 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6069492B2 (ja) * 2012-04-25 2017-02-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｃ型肝炎ウイルス阻害剤
WO2013163262A1 (en) 2012-04-25 2013-10-31 Theravance, Inc. Piperazine-piperidine compounds as hepatitis c virus inhibitors
WO2013165796A1 (en) * 2012-05-03 2013-11-07 Theravance, Inc. Crystalline form of a pyridyl-piperazinyl hepatitis c virus inhibitor
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法
CN112409336B (zh) * 2017-11-27 2021-09-14 常州寅盛药业有限公司 适于工业化生产的达卡他韦起始原料的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421908D0 (en) * 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
DK1940786T3 (da) * 2005-09-16 2010-11-08 Arrow Therapeutics Ltd Biphenylderivater og deres anvendelse ved behandling af hepatitis C
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101558059B (zh) * 2006-08-11 2014-12-03 百时美施贵宝公司 丙型肝炎病毒抑制剂
US7910722B2 (en) * 2007-07-05 2011-03-22 Florida State University Research Foundation RNAi therapeutic for treatment of hepatitis C infection
AU2008350327B2 (en) 2008-02-12 2013-09-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2750577A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
UY32462A (es) * 2009-02-23 2010-09-30 Arrow Therapeutics Ltd Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2012061552A1 (en) * 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus
BR112014010401A8 (pt) 2011-11-03 2017-12-19 Theravance Inc Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014532716A (ja) * 2011-11-03 2014-12-08 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー フラグメント｛２−［４−（ビフェニル−４−イル）−１ｈ−イミダゾ−２−イル］ピロリジン−１−カルボニルメチル｝アミンを含む棒状ｃ型肝炎ウイルス阻害剤

Also Published As

Publication number Publication date
CN103189371B (zh) 2015-04-01
JP2013544812A (ja) 2013-12-19
TW201249827A (en) 2012-12-16
US8921372B2 (en) 2014-12-30
EP2635571B1 (en) 2015-08-12
EP2635571A1 (en) 2013-09-11
US20150071878A1 (en) 2015-03-12
CA2814534A1 (en) 2012-05-10
WO2012061552A1 (en) 2012-05-10
US20120114600A1 (en) 2012-05-10
ES2548286T3 (es) 2015-10-15
CN103189371A (zh) 2013-07-03
US9260414B2 (en) 2016-02-16
AR083757A1 (es) 2013-03-20

Similar Documents

Publication Publication Date Title
JP5891235B2 (ja) Ｃ型肝炎ウイルスの新規阻害剤
JP6082747B2 (ja) フラグメント｛２−［４−（ビフェニル−４−イル）−１ｈ−イミダゾ−２−イル］ピロリジン−１−カルボニルメチル｝アミンを含む棒状ｃ型肝炎ウイルス阻害剤
JP6069491B2 (ja) Ｃ型肝炎ウイルス阻害剤としてのピペラジン−ピペリジン化合物
JP6069492B2 (ja) Ｃ型肝炎ウイルス阻害剤
NZ623846B2 (en) Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(bi phenyl-4-yl) -1h-imidazo-2-yl] pyrrolidine-1-carbonlymethyl} amine

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150609

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160222

R150 Certificate of patent or registration of utility model

Ref document number: 5891235

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees